HK's Genscript Biotech jumps on deal to commercialize COVID-19 mRNA vaccine

Genscript Biotech

25/10/2021 04:27

** Shares of China's Genscript Biotech Corp  1548.HK  rise
as much as 5.6% to HK$34.75, their highest since Sept. 13,
extending gains for the second session
    ** Jiangsu-based biotech firm says its unit has entered into
services agreement with Suzhou Abogen Biosciences and Yuxi
Walvax Biotechnology on the biologic license application of mRNA
vaccines and its commercial production  urn:newsml:reuters.com:*:nFWN2RI0PU
    ** Says its unit, Jiangsu GenScript ProBio Biotech, shall be
the exclusive services supplier for the commercial production of
plasmid for the project, while Walvax  300142.SZ  shall be the
applicant for the project 
    ** Says Phase III clinical trials of the project have been
approved by the drug administration authorities of Mexico,
Indonesia and Nepal, and the modular plant of Walvax has been in
operation since September 2021 for the commercial production of
the COVID-19 mRNA vaccine
    ** Hang Seng healthcare index  .HSCIH  gains 0.4%, while the
Hang Seng Composite Index  .HSCI  slips 0.1%
    ** The Hang Seng China Enterprises Index  .HSCE  eases 0.1%,
while the benchmark index  .HSI  climbs 0.1%
    ** As of last close, the stock had soared 191.7% this year

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))